Unity Biotechnology Inc Reports Results For The Quarter Ended In March: Earnings Summary

Unity Biotechnology

15/05/2024 21:36

* UNITY Biotechnology Inc  UBX.OQ  reported a quarterly
adjusted
loss of 34 cents​​ per share for the quarter ended in March,
higher than the same quarter last year, when the company
reported EPS of -76 cents.  The mean expectation of
three analysts for the quarter was for a loss of 48 cents per
share. Wall Street expected results to range from -57 cents
to -38 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * UNITY Biotechnology Inc's reported EPS for the quarter was
a
loss of 34 cents​.
    * The company reported a quarterly loss of $5.79 million.
    * UNITY Biotechnology Inc shares had fallen by 6.7% this
quarter and lost 20.7% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 7% in
the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is  "buy."

Wall Street's median 12-month price target for UNITY
Biotechnology Inc is $6.00 
This summary was machine generated from LSEG data May 15 at
08:36 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.48          -0.34          Beat
 Dec. 31 2023      -0.72          -0.28          Beat
 Sep. 30 2023      -0.96          -0.66          Beat
 Jun. 30 2023      -0.86          -0.85          Beat